← SynDRA
AFATINIB
SynDRA canonical compound SYN0022649 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | EGFR | ERBB2 | ERBB4 |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ERBB2
- EGFR
- ERBB4
- ABL1
- MAPK14
- MAPK9
- MAPKAPK2
- MET
- MKNK1
- MKNK2
- MYLK
- PHKG1
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- ERBB4 INHIBITOR
- Receptor protein-tyrosine kinase erbB-4 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- RET
- ADRA2B
- MST1R
- SYK
- LYN
- ROS1
- KCNH2
- OXSR1
- PDK1
- PI4KB
- OLA1
- PGRMC1
- PGR
- PEBP1
- OPA1
- OPRD1
- PDXK
- PDPK1
- OPRK1
- OPRM1
- PDGFRB
- PAICS
- PDGFRA
- PDE4D
- PIK3C2B
- PCYT1A
- PASK
- PAK6
- PAK5
- PAK4
- PAK3
- PAK2
- PAK1
- PDE3A
- AAK1
- PIK3C2G
- NUAK1
- PRKAG1
- PRKACG
- PRKACB
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- GAMT
- GNMT
- HNMT
- IFNB1
- IFNG
- IL3
- KSYK
- NNMT
- NSD2
- NTM1A
- NTMT1
- PNMT
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- GILOTRIF
- Gilotrif
- tovok
- afatinib dimaleate
- gilotrif
- BIBW2992
- afatinib maleate
- BIBW-2992
- TOMTOVOK
- TOVOK
- (E/Z)-AFATINIB
- (E/Z)-BIBW 2992
- AFATINIB (BIBW2992)
- Afatinib dimaleate
- AFATINIB FREE BASE
- BIBW2992 (AFATINIB)
- BIBW2992-MA2
- BIBW2992AFATINIBTOVOKS1011
- Giotrif
- NSC-750691
- Tomtovok
- Tovok
- Tovok (TN)
- Tovok, BIBW2992
- EGFR inhibitor 2nd gens
- Afatinib (diMaleate)
- UNII-V1T5K7RZ0B
- BIBW 2992MA2
- Afatinib dimaleate [USAN]
- V1T5K7RZ0B
- CHEBI:76003
- Afatinib (BIBW2992) Dimaleate
- Afatinib maleate
- Afatinib dimaleate (USAN)
- Gilotrif (TN)
- Giotrif (TN)
- Afatinib maleate (JAN)
- BIBW2992 MA2
Reported adverse events
- Cheilitis
- Conjunctivitis
- Cystitis
- Dry skin
- Epistaxis
- Nausea
- Paronychia
- Pruritus
- Pyrexia
- Rash
- Stomatitis
- Toxic epidermal necrolysis
Look up AFATINIB in the interactive SynDRA portal →